Skip to main content

Haoming Qiu, M.D.

Contact Information

Phone Numbers

Appointment: (585) 275-2171

Appointment: (585) 396-6180

Office: (585) 275-5625

URMFGA member of the University of Rochester Medical Faculty Group

groupAn Accountable Health Partner

assignmentAccepting New Patients

Faculty Appointments

Patient Care Setting

Radiation Oncology


Professional Background

Dr. Haoming (Carl) Qiu is a radiation oncologist at the University of Rochester Medical Center seeing patients at both Wilmot Cancer Center in Rochester and Sands Cancer Center in Canandaigua. Dr. Qiu received his medical education at the Johns Hopkins University School of Medicine in Baltimore, MD and completed his residency in radiation oncology at the University of Rochester Medical Center. Dr. Qiu brings a high level of technical expertise along with a friendly and optimistic attitude in caring for his patients.

In addition to external beam radiation, Dr. Qiu also treats patient with the following radiopharmaceutical therapies.

1.Lutathera (lutetium Lu 177 dotatate) PRRT (Peptide Receptor Radionuclide Therapy) for patients with neuroendocrine tumors
2. Pluvicto (lutetium Lu 177 PSMA-617) for patients with prostate cancer
3. Therasphere (Y90) radioembolization for patients with liver cancers.

If you are interested in a consultation, please have your doctor call our office for a referral. (585) 275-5625.


Dr. Qiu's research focuses on the use of radiation therapy in the treatment of gastrointestinal, lung and prostate cancers. He is also interested in the use of theranostics and radiopharmaceuticals for the treatment of malignant conditions. Please see below for a number of clinical trials that Dr. Qiu is leading at the University of Rochester.



MD | Johns Hopkins University

Post-doctoral Training & Residency

07/01/2013 - 06/30/2016
Residency in Radiation Oncology at University of Rochester Medical Center

07/02/2012 - 06/30/2013
Residency in Radiation Oncology at Loyola University Medical Center

06/23/2011 - 06/22/2012
Internship in Internal Medicine at Sinai Hospital Of Baltimore

VIEW ALL expand_more


Roentgen Resident/Fellow Research Award
Sponsor: RSNA Research and Education Foundation
Location: University of Rochester Medical Center

Excellence in Medical Student Research
Location: Johns Hopkins University School of Medicine

Clinical Trials

A Pragmatic Randomized Phase III Trial Evaluating Total Ablative Therapy for Patients With Limited Metastatic Colorectal Cancer: Evaluating Radiation, Ablation, and Surgery (ERASur)

Lead Researcher: Haoming Qiu

This phase III trial compares total ablative therapy and usual systemic therapy to usual systemic therapy alone in treating patients with colorectal cancer that has spread to up to 4 body sites (limited metastatic). The usual approach for patients who are not participating in a study is treatment with intravenous (IV) (through a vein) and/or oral medications (systemic therapy) to help stop the cancer sites from getting larger and the spread of the cancer to additional body sites. Ablative means that the intention of the local treatment is to eliminate the cancer at that metastatic site. The ablative local therapy will consist of very focused, intensive radiotherapy called stereotactic ablative radiotherapy (SABR) with or without surgical resection and/or microwave ablation, which is a procedure where a needle is temporarily inserted in the tumor and heat is used to destroy the cancer cells. SABR, surgical resection, and microwave ablation have been tested for safety, but it is not scientifically proven that the addition of these treatments are beneficial for your stage of cancer. The addition of ablative local therapy to all known metastatic sites to the usual approach of systemic therapy could shrink or remove the tumor(s) or prevent the tumor(s) from returning.

View Study Details

Phase III Prospective Randomized Trial of Primary Lung Tumor Stereotactic Body Radiation Therapy Followed by Concurrent Mediastinal Chemoradiation for Locally Advanced Non-Small Cell Lung Cancer

Lead Researcher: Haoming Qiu

This phase III trial compares the effect of adding stereotactic body radiation therapy (SBRT) to standard treatment (image guided radiation therapy [IGRT] and chemotherapy followed by immunotherapy with durvalumab) versus standard treatment alone in treating patients with non-small cell lung cancer that cannot be treated by surgery (inoperable). SBRT uses special equipment to position a patient and deliver radiation to tumors with high precision. This method may kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. IGRT is a type of radiation that uses a computer to create picture of the tumor, to help guide the radiation beam during therapy, making it more accurate and causing less damage to healthy tissue. Standard chemotherapy used in this trial consists of combinations of the following drugs: cisplatin, carboplatin, paclitaxel, pemetrexed, and etoposide. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of tumor cells. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Paclitaxel is in a class of medications called antimicrotubule agents. It works by stopping the growth and spread of tumor cells. Pemetrexed is in a class of medications called antifolate antineoplastic agents. It works by blocking the action of a certain substance in the body that may help tumor cells multiply. Etoposide is in a class of medications known as podophyllotoxin derivatives. It blocks a certain enzyme needed for cell division and DNA repair and may kill tumor cells. Immunotherapy with durvalumab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Adding SBRT to the standard treatment of IGRT with chemotherapy and immunotherapy may be more effective at treating patients with inoperable non-small cell lung cancer than giving the standard treatment alone.

View Study Details

A Randomized Phase II Study De-Intensified ChemoRadiation for Early-Stage Anal Squamous Cell Carcinoma (DECREASE)

Lead Researcher: Haoming Qiu

This phase II trial studies how well lower-dose chemotherapy plus radiation (chemoradiation) therapy works in comparison to standard-dose chemoradiation in treating patients with early-stage anal cancer. Drugs used in chemotherapy, such as mitomycin, fluorouracil, and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Giving chemotherapy with radiation therapy may kill more tumor cells. This study may help doctors find out if lower-dose chemoradiation is as effective and has fewer side effects than standard-dose chemoradiation, which is the usual approach for treatment of this cancer type.

View Study Details


Journal Articles

Mills BN; Qiu H; Drage MG; Chen C; Mathew JS; Garrett-Larsen J; Ye J; Uccello TP; Murphy JD; Belt BA; Lord EM; Katz AW; Linehan DC; Gerber SA. "Modulation of the human pancreatic ductal adenocarcinoma immune microenvironment by stereotactic body radiotherapy". Clin Cancer Res. 2022; 28(1): 150-162.

Komisarof J, Qiu H, Velez MJ, Mulford D. "Anterior mediastinal large cell neuroendocrine carcinoma with elevated AFP: A case report and review." Molecular and clinical oncology.. 2021 Feb; 14(2):34. Epub 2020 Dec 22.

Battaglia NG; Uccello TP; Hughson A; Garrett-Larsen J; Caldon JJ; Qiu H; Gerber SA; Lord EM. "Co-administration of a clinically relevant dexamethasone dosage with ablative radiotherapy reduces peripheral lymphocytes but does not alter in vivo intratumoral lymphocyte phenotype or inhibit efficacy of radiotherapy in a murine colorectal tumor model." International journal of radiation oncology, biology, physics. 2021; 111(1): 284-296.

Books & Chapters

Chapter Title: Programed Death Receptor-1 (PD-1)
Book Title: Medical Radiology: Radiation Oncology: Advances in Radiation Oncology in Lung Cancer
Author List: Qiu H, Chen Y
Edited By: Jeremic B
Published By: Springer 2021 in New York

Chapter Title: Oligometastatic Disease – Basic Aspects and Clinical Results
Book Title: Medical Radiology: Radiation Oncology: Advances in Radiation Oncology in Lung Cancer
Author List: Sakthivel G, Singh DP, Qiu H, Milano MT
Edited By: Jeremic B
Published By: Springer 2021



At URMC, we believe that patients should be empowered to make the right decisions regarding their personal healthcare. To do so, transparency is critical. URMC partners with Press Ganey, to survey our patients about all aspects of their care experience. We are now putting this pertinent information at your fingertips by displaying star ratings for our providers along with anonymous patient comments on our website. This will help you make better-informed choices about how and with whom you seek care. Click here to learn more about the surveys used to generate this vital information.